Sentinel Lymph Node Biopsy Calculators for Informed Decision-Making
Menée en Suède à partir de données portant sur 10 089 patients atteints d'un mélanome cutané et ayant bénéficié d'une biopsie du ganglion sentinelle entre 2007 et 2021, cette étude compare la performance de deux modèles pour prédire le statut du ganglion sentinelle
National Comprehensive Cancer Network (NCCN) guidelines recommend sentinel node biopsy (SNB) for patients with melanomas at least 1 mm in depth; however, selecting low-risk patients remains challenging. Models incorporating multiple clinical and pathologic variables associated with tumor aggressiveness (such as mitotic index and ulceration) may enable more reliable selection of low-risk patients to safely avoid SNB or benefit from SNB. Two models have been developed to assist in this decision-making process, from Memorial Sloan Kettering Cancer Center (MSKCC) and from the Melanoma Institute of Australia (MIA).
JAMA Surgery , éditorial, 2023